(Q37225249)

English

A polymorphism at the 3'-UTR region of the aromatase gene is associated with the efficacy of the aromatase inhibitor, anastrozole, in metastatic breast carcinoma

scientific article published on 13 September 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

A polymorphism at the 3'-UTR region of the aromatase gene is associated with the efficacy of the aromatase inhibitor, anastrozole, in metastatic breast carcinoma (English)

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

1 reference

based on heuristic

inferred from title

author name string

Lei Liu

1

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Yu-Xian Bai

2

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Jian-Hua Zhou

3

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Xiu-Wei Sun

4

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Hong Sui

5

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Wen-Jie Zhang

6

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Heng-Heng Yuan

7

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Rui Xie

8

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Xiao-Li Wei

9

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Ting-Ting Zhang

10

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Peng Huang

11

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Yan-Jing Li

12

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Jing-Xuan Wang

13

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Shu Zhao

14

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Qing-Yuan Zhang

15

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

language of work or name

0 references

publication date

13 September 2013

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

International Journal of Molecular Sciences

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

14

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

9

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

18973-18988

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

copyright license

Creative Commons Attribution 4.0 International

13 September 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Regulation of aromatase expression in breast cancer treated with anastrozole neoadjuvant therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794816

6 September 2017

Cancer treatment and survivorship statistics, 2012

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794816

6 September 2017

The role of the fat mass and obesity associated gene (FTO) in breast cancer risk

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794816

6 September 2017

Genetic polymorphisms and obesity influence estradiol decline during the menopause

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794816

6 September 2017

Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794816

6 September 2017

A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794816

6 September 2017

Integrated view on 17beta-hydroxysteroid dehydrogenases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794816

6 September 2017

The obesity-associated FTO gene encodes a 2-oxoglutarate-dependent nucleic acid demethylase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794816

6 September 2017

THE HARDY-WEINBERG LAW.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794816

6 September 2017

Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794816

6 September 2017

Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794816

6 September 2017

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794816

6 September 2017

SNPs in cancer research and treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794816

6 September 2017

The role of aromatase inhibitors in the treatment of metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794816

6 September 2017

Molecular epidemiology of sporadic breast cancer. The role of polymorphic genes involved in oestrogen biosynthesis and metabolism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794816

6 September 2017

Hormonal therapy in postmenopausal women with breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794816

6 September 2017

Genetic polymorphisms of cytochrome P450 19 and 1B1, alcohol use, and breast cancer risk in Korean women

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794816

6 September 2017

A prospective study of endogenous estrogens and breast cancer in postmenopausal women

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794816

6 September 2017

Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794816

14 September 2017

Human 17beta-hydroxysteroid dehydrogenases types 1, 2, and 3 catalyze bi-directional equilibrium reactions, rather than unidirectional metabolism, in HEK-293 cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794816

14 September 2017

Aromatase and breast cancer susceptibility

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794816

26 June 2018

Characterization of structural and functional properties of human 17 beta-hydroxysteroid dehydrogenase type 1 using recombinant enzymes and site-directed mutagenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794816

26 June 2018

Obesity and physical inactivity are related to impaired physical health of breast cancer survivors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794816

3 September 2018

Aromatase inhibitors in obese breast cancer patients are not associated with increased plasma estradiol levels

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794816

3 September 2018

A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794816

3 September 2018

Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794816

3 September 2018

Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794816

3 September 2018

Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794816

3 September 2018

17beta-hydroxysteroid dehydrogenase type 1 is an independent prognostic marker in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794816

3 September 2018

The CYP19 gene codon 39 Trp/Arg polymorphism increases breast cancer risk in subsets of premenopausal Japanese.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794816

3 September 2018

Her2/neu expression predicts the response to antiaromatase neoadjuvant therapy in primary breast cancer: subgroup analysis from celecoxib antiaromatase neoadjuvant trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794816

3 September 2018

Polymorphisms associated with circulating sex hormone levels in postmenopausal women

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794816

3 September 2018

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794816

3 September 2018

Association of genetic polymorphisms in CYP19 and CYP1A1 with the oestrogen receptor-positive breast cancer risk

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794816

3 September 2018

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety upda

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794816

3 September 2018

A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794816

3 September 2018

Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794816

3 September 2018

A comprehensive haplotype analysis of CYP19 and breast cancer risk: the Multiethnic Cohort

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794816

3 September 2018

Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794816

3 September 2018

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794816

3 September 2018

Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3794816

3 September 2018

Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study

1 reference

https://pubmed.ncbi.nlm.nih.gov/24065098

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety, activity and estrogen inhibition by exemestane in postmenopausal women with advanced breast cancer: a phase I study

1 reference

https://pubmed.ncbi.nlm.nih.gov/24065098

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

1 reference

https://pubmed.ncbi.nlm.nih.gov/24065098

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Genetic polymorphisms of the CYP19A1 gene and breast cancer survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/24065098

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/24065098

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.3390/IJMS140918973

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37225249&oldid=1863979175"